Influence of B2 Receptor Antagonists on Bradykinin-induced Vasodilation and Edema Formation in Isolated Rabbit Hindlimbs

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 1995 May 1

PMID 7655996

Authors

I Breil

T Koch

S Goldberg

H NEUHOF

K van Ackern

Affiliations

Soon will be listed here.

Abstract

In search of new possibilities to prevent acute inflammatory vascular reaction, we examined the effect of two selective B2 receptor antagonists, CP 0127 ([Bissuccimidohexane (L-Cys6)-1] and HOE 140 (D-Arg[Hyp3, Thi5, D-Tic7, Oic8]BK), on changes in perfusion pressure and on edema formation caused by bradykinin (BK) in the isolated perfused rabbit hindlimbs. CP 0127 and HOE 140 were added to the perfusion fluid 2 min prior to the first BK-administration (5 x 10(-9) mol/l). A second BK-stimulation was performed after 30 minutes. The antagonists were tested in groups of 6 experiments each at concentrations of 10(-6) mol/l, 5 x 10(-9) mol/l and 10(-10) mol/l. CP 0127 was also tested in a concentration of 10(-8) mol/l. The application of BK resulted in an acute decrease of the mean arterial pressure and in a continual edema formation, reflected by an increase of organ weight (controls, n = 6). Pretreatment with CP 0127 as well as with HOE 140 attenuated dose-dependently the BK-induced vasodilation (p < 0.005) and edema formation. The current results indicate that CP 0127 and HOE 140 are able to reduce BK-induced effects on vascular tone and edema formation.

References

FURCHGOTT R . The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984; 24:175-97. DOI: 10.1146/annurev.pa.24.040184.001135. View

Weipert J, Hoffmann H, Siebeck M, Whalley E . Attenuation of arterial blood pressure fall in endotoxin shock in the rat using the competitive bradykinin antagonist Lys-Lys-[Hyp2, Thi5,8, DPhe7]-Bk (B4148). Br J Pharmacol. 1988; 94(2):282-4. PMC: 1853989. DOI: 10.1111/j.1476-5381.1988.tb11526.x. View

Waeber B, Aubert J, Nussberger J, Vavrek R, Stewart J, Brunner H . Influence of bradykinin on blood pressure regulation of spontaneously hypertensive rats maintained on different sodium intakes. Clin Exp Pharmacol Physiol. 1987; 14(8):659-64. DOI: 10.1111/j.1440-1681.1987.tb01887.x. View

Regoli D, Rhaleb N, Dion S, Drapeau G . New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol Sci. 1990; 11(4):156-61. DOI: 10.1016/0165-6147(90)90067-I. View

MILLER F, Sims D . Contractile elements in the regulation of macromolecular permeability. Fed Proc. 1986; 45(2):84-8. View

Vavrek R, Stewart J . Development of bradykinin antagonists: structure-activity relationships for new categories of antagonist sequences. Adv Exp Med Biol. 1989; 247B:395-400. DOI: 10.1007/978-1-4615-9546-5_65. View

Bond A, Breipohl G, Worthy K, Campion G, Dieppe P, Bhoola K . Metabolism and characterisation of kinins and Hoe 140 (kinin antagonist) in the synovial fluid of patients with inflammatory joint diseases. Agents Actions Suppl. 1992; 38 ( Pt 1):582-9. DOI: 10.1007/978-3-0348-7321-5_71. View

Svensjo E, Arfors K, Raymond R, Grega G . Morphological and physiological correlation of bradykinin-induced macromolecular efflux. Am J Physiol. 1979; 236(4):H600-6. DOI: 10.1152/ajpheart.1979.236.4.H600. View

Steranka L, Manning D, Dehaas C, Ferkany J, Borosky S, Connor J . Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci U S A. 1988; 85(9):3245-9. PMC: 280181. DOI: 10.1073/pnas.85.9.3245. View

10.

Neppl H, NEUHOF H, Afflerbach F, Llach Puig Neppl J, Berghofer A . Bradykinin-induced oedema formation proceeds from B2 receptor stimulation and is potentiated by concomitantly released prostaglandins. Acta Physiol Scand. 1991; 142(2):141-7. DOI: 10.1111/j.1748-1716.1991.tb09141.x. View

11.

Regoli D, Barabe J . Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980; 32(1):1-46. View

12.

Steranka L, Burch R, Vavrek R, Stewart J, Enna S . Multiple bradykinin receptors: results of studies using a novel class of receptor antagonists. Adv Exp Med Biol. 1988; 236:111-27. DOI: 10.1007/978-1-4757-5971-6_9. View

13.

Hock F, Wirth K, Albus U, Linz W, Gerhards H, Wiemer G . Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991; 102(3):769-73. PMC: 1917958. DOI: 10.1111/j.1476-5381.1991.tb12248.x. View

14.

Vavrek R, Stewart J . Competitive antagonists of bradykinin. Peptides. 1985; 6(2):161-4. DOI: 10.1016/0196-9781(85)90033-6. View

15.

White M, MILLER F, Heuser L, Pietsch C . Human malignant ascites and histamine-induced protein leakage from the normal microcirculation. Microvasc Res. 1988; 35(1):63-72. DOI: 10.1016/0026-2862(88)90050-7. View

16.

Whalley E, Solomon J, Modafferi D, Bonham K, Cheronis J . CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992; 38 ( Pt 3):413-20. View

17.

Rhaleb N, Telemaque S, Rouissi N, Dion S, Jukic D, Drapeau G . Structure-activity studies of bradykinin and related peptides. B2-receptor antagonists. Hypertension. 1991; 17(1):107-15. DOI: 10.1161/01.hyp.17.1.107. View

18.

Rhaleb N, Rouissi N, Jukic D, Regoli D, Henke S, Breipohl G . Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol. 1992; 210(2):115-20. DOI: 10.1016/0014-2999(92)90661-m. View

19.

Cheronis J, Whalley E, Nguyen K, Eubanks S, Allen L, Duggan M . A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem. 1992; 35(9):1563-72. DOI: 10.1021/jm00087a010. View

20.

Svensjo E, Grega G . Evidence for endothelial cell-mediated regulation of macromolecular permeability by postcapillary venules. Fed Proc. 1986; 45(2):89-95. View